tbuckley/cabot-search huggingface dataset:
Recreational exercise and quality of life among women undergoing adjuvant chemotherapy for breast cancer
Authors: C. A. Jacobson, S. M. Talbot, L. T. Vahdat, A. B. Troxel, L. Shriberg, L. B. Brafman, A. D. Tiersten
Journal: Journal of Clinical Oncology (2004)

8195 Background: The negative relationship between exercise and treatment-related toxicity in women with breast cancer was first noted in the mid-1980s. Since then a number of randomized studies have demonstrated the benefits of exercise during adjuvant therapy for breast cancer with respect to fatigue, emotional distress, functional ability, and quality of life (QOL). In order to further characterize this relationship we have conducted a study examining the impact of exercise on chemotherapy-related toxicities and QOL. Methods: A cohort of forty women completed a modified Godin and FACT-B QOL questionnaire at the beginning, midpoint, and end of treatment with adjuvant chemotherapy. Additional outcomes were toxicity, use of growth factors, treatment delay, and hospitalizations. Toxicity was evaluated and analyzed both by grade and by type based on the most common toxicities encountered. Results: There was no statistically significant correlation between exercise intensity and QOL, toxicity, or the requirement for growth factors, treatment delays, or hospitalization, both when the data was and was not stratified by chemotherapy regimen. Interestingly, when the patients' average QOL scores were correlated with the same variables, no statistically significant correlation was found. However, QOL was significantly lower for those patients receiving chemotherapy regimens consisting of adriamycin, cyclophosphamide, and paclitaxel (in any order) than those receiving cyclophosphamide, methotrexate, and 5-fluorouracil(p=0.0164). Conclusions: The results of this cohort study do not implicate a role for exercise in the diminution of chemotherapy-related toxicity nor the improvement of QOL for breast cancer patients undergoing adjuvant chemotherapy. However, this study was limited by design and patient numbers. That it failed to identify a difference in QOL among the patients who experienced the most severe toxicities, and those who required growth factors, treatment delays, or hospitalization suggests that it was not powerful enough to detect such differences among patients who engaged in different exercise intensities. No significant financial relationships to disclose.
Laboratory and clinical studies of high anti-lymphoma potency with anti-CD20 veltuzumab and differentiation from rituximab
Authors: D. M. Goldenberg, C. Chang, E. A. Rossi, T. M. Cardillo, W. A. Wegener, N. Teoh, J. P. Leonard, L. E. Fayad, B. Coiffier, F. Morschhauser
Journal: Journal of Clinical Oncology (2008)

3043 Background: Veltuzumab (hA20) is a humanized 2nd generation anti-CD20 monoclonal antibody (mAb) under evaluation for B- cell malignancies and autoimmune diseases that differs from chimeric rituximab by one amino acid in CDR3 of VH and completely different framework regions derived from epratuzumab (anti-CD22 humanized mAb). Methods: In-vitro comparisons to rituximab using human CD20+ lymphoma cell lines involved Scatchard analysis of binding properties, off-rates, lipid-raft trafficking, growth-inhibition, apoptosis, ADCC, and CDC. In-vivo therapy experiments involved xenografted human Burkitt lymphoma line, and B-cell depletion was studied in Cynomolgus monkeys given i.v. and s.c. doses. In phase 1–2 clinical trials, patients (pts) with relapsed follicular (FL) or other B-cell NHL received 80, 120, 200, 375 and 750 mg/m2 veltuzumab doses i.v. weekly x 4. Results: In-vitro, veltuzumab demonstrated more potent CDC than rituximab with the Daudi cell line and had significantly reduced off-rates (longer residence times) for all 3 lymphoma cell lines (Daudi, Raji, WSU-FSCCL); otherwise, the anti-proliferative, apoptotic, and ADCC effects and binding properties of the two antibodies were similar. Lymphoma xenograft models showed antitumor effects of veltuzumab at doses as low as 0.05–0.1 μg iv/ip or sc. Clinically, durable complete responses (CR/CRu) occurred in 28% (14/50) of pts with follicular NHL (median duration of response, 19.7 mo.), including all veltuzumab dose levels tested. Most importantly, at the lowest dose (80 mg/m2 ), veltuzumab depleted circulating B cells after a single infusion and 5/8 (63%) patients had objective responses, including 2 (25%) achieving CR/CRu. Similar to epratuzumab, lower doses were administered within 2 h for 1st infusion and 1 h subsequently, and no infusion or other toxicities beyond grade 1–2, or HAHA responses, were observed. Conclusions: These findings suggest that veltuzumab has differentiating efficacy and safety properties. The demonstration of effective low i.p./i.v. doses with additional corroborating evidence of efficacy of the s.c. formulation in murine and monkey models justify clinical trials with low-dose i.v. veltuzumab, as well as s.c. veltuzumab, which are now in progress. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Immunomedics Immunomedics Immunomedics
The impact of insomnia on patient satisfaction with quality of life in advanced cancer: A longitudinal analysis
Authors: L. Cain, K. Campbell, K. Gilbert, J. J. Stark, C. G. Lis, T. C. Birdsall, J. F. Grutsch, S. Williams, D. Gupta
Journal: Journal of Clinical Oncology (2008)

20501 Background: Insomnia is one of the most common and disabling symptoms experienced by cancer patients. We prospectively quantified the relationship between insomnia and patient satisfaction with quality of life (QoL) in advanced cancer. Methods: 295 cancer patients treated at Cancer Treatment Centers of America between 10/03 and 10/05 for a period of 3 months and who completed 2 QoL questionnaires at both baseline and 3 months. Insomnia was measured using the EORTC QLQ-C30 insomnia subscale. Scores ranged from 0 - 100, higher scores indicating more insomnia. Patient satisfaction with QoL was measured using Ferrans & Powers Quality of Life Index (QLI). Scores ranged from 0 - 30, higher scores indicating better QoL. The mean insomnia scores were compared using paired-samples t test across the 2 time periods. Results: Of 295 patients, 140 were males and 155 females. 73 had breast cancer, 65 lung, 39 prostate, 33 colorectal, 12 pancreas and 73 had other cancers. 150 were newly diagnosed and 145 had received prior treatment elsewhere. The mean insomnia scores at baseline and 3 months were 41.2 (more insomnia) and 32.9 (less insomnia) respectively (p=0.001). Similarly, the mean QLI health scores at baseline and 3 months were 17 (low QoL) and 18.3 (better QoL) respectively (p=0.002). At baseline, after controlling for age, gender, prior treatment history, and tumor stage at diagnosis, every 10-unit increase in insomnia was significantly associated with 0.86 (p < 0.001), 0.21 (p = 0.01), 0.48 (p < 0.001), 0.27 (p < 0.007) and 0.53 (p < 0.001) unit decrease in QLI health, social, psychological, family and overall QoL respectively. At 3 months, every 10-unit increase in insomnia was significantly associated with 0.87 (p < 0.001), 0.35 (p = 0.001), 0.51 (p < 0.001), 0.34 (p = 0.003) and 0.59 (p < 0.001) unit decrease in QLI health, social, psychological, family and overall QoL. Conclusions: We found that insomnia is a strong correlate of QoL independent of age, gender, prior treatment history and tumor stage at diagnosis during the first 3 months of treatment. Despite receiving aggressive cancer therapy, patients treated at our integrative cancer center reported statistically significant improvements in insomnia and overall QoL. No significant financial relationships to disclose.
Jesse’s Song
Authors: Gary Stein
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 11874: Inhibition of Cytosolic p53 Preserves Mitochondrial Integrity and Prevents Cardiac Aging
Authors: Atsushi Hoshino, Satoaki Matoba, Maki Katamura, Yoshifumi Okawa, Makoto Ariyoshi, Satoshi Kaimoto, Yuichiro Mita, Hiroaki Matsubara
Journal: Circulation (2012)

Aging is a complex process influenced by diverse molecular factors with accumulation of organellar, cellular, and organ damage, leading to functional decline and increased susceptibility to disease...
The Relevance Of CD4 Cell Counts and Abnormal Bone Marrow Findings Among HIV-Infected Patients
Authors: Thanawat Rattanathammethee, Lalita Norasetthada, Adisak Tantiworawit, Ekarat Rattarittamrong, Chatree Chai-adisaksopha, Sasinee Hantrakool, Weerasak Nawarawong
Journal: Blood (2013)
Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN), a new national cancer registry
Authors: W. Curran, A. Chen, P. Harari, B. Murphy, S. Wong, L. Bellm, D. Gamber, D. Dawson, K. Ang
Journal: Journal of Clinical Oncology (2006)

5583 Background: Registries can be invaluable for describing patterns of care for a population of patients (pts). Most cancer registries, however, do not possess sufficient breadth or depth to provide a complete and reliable picture of clinical practice. We report the launch of LORHAN, a new national registry of head and neck carcinoma (HNC) pts. LORHAN is designed to extend current cancer registries by providing detailed data on radiation and/or cancer drugs delivered to HNC pts in all practice settings. Methods: This is a prospective, multi-center, longitudinal, observational registry. Pts with newly diagnosed HNC, scheduled to receive radiotherapy or drug therapy, ≥18 years of age and providing written informed consent are being enrolled. Patients participating in clinical trials are eligible for LORHAN. The primary objective of the registry is to describe, in detail, patterns of care for HNC pts. The secondary objectives are to document outcome by treatment regimen, determine the incidence and severity of major toxicities and to identify supportive care received for managing treatment-related complications. Pts are entered in the registry from the time of initial diagnosis and are followed for at least 2 years and up to 10 years. Detailed information on initial treatment and re-treatment is collected. Data entry is electronic and incorporates encrypted point-to-point data transfer via secure HTTP protocols. Physician and patient confidentiality are strictly maintained. Participating practitioners can review and compare their data on a real-time basis to the database. Registry pts may be linked to the NDI to minimize lost to follow-up. Analyses of data are primarily descriptive. Results: LORHAN was launched in Oct. 2005, and as of Dec., 7 sites have received IRB approval and 3 pts have been enrolled. Of the 7 sites, 1 is an academic site and the remaining are community-based practices. An additional 21 sites (17 academic, 4 community) are at various stages of participation. More than 100 medical oncologists and radiation oncologists are anticipated to participate and approximately 26,000 pts will be eligible each year. Accrual status will be updated. Conclusions: LORHAN is a new national initiative that may further the understanding of the care of HNC pts across practice settings. [Table: see text]
PARP expression in early breast cancer and its predictive value for response to neoadjuvant chemotherapy.
Authors: S. Loibl, B. Mueller, G. Von Minckwitz, J. U. Blohmer, A. d. Bois, J. B. Huober, F. Fend, J. Budczies, C. Denkert
Journal: Journal of Clinical Oncology (2010)

10511 Background: The polyadenosine diphosphate [ADP]-ribose polymerase-1 (PARP-1) plays a key role in the genomic stability, transcription, chromatin remodelling and apoptosis. Increased expression is considered to be associated with resistance to DNA damage- inducing therapeutic agents. We investigated PARP expression in various hormone (HR) / HER2 receptor subtypes of early breast cancer. Methods: Tissue microarrays from core biopsies of 646 patients recruited to the phase III GeparTrio trial, who received neoadjuvant 6-8 cycles TAC/NX chemotherapy, were centrally stained immunohistochemically for PARP, ER, PgR and HER2. Cytoplasmatic and nuclear staining of PARP was assessed with regard to intensity and percentage and scored as low, medium or high expression. Its predictive value for pathological complete response (pCR; defined as no invasive residuals in breast and nodes) was evaluated. Results: Overall, cytoplasmatic PARP expression was high in 23.7%, medium in 50.6% and low in 25.7% of patients. High expression was found in 18.8% of 309 HR+/HER2-, 20.0% of 145 HR+/HER2+, 34.4% of 61 HR-/HER2+ and 34.2% of 114 HR-/HER2- tumours (p=0.001). High PARP expression was significantly correlated with undifferentiated tumour pattern (p<0.001), non-lobular cancers (p<0.001), negative HR (p<0.001). PCR rate was 26.5% (95% CI: 20.1-30.0), 19.1% (95% CI: 15.2-23.7), and 8.9% (95% CI: 4.7-13.2) in patients with high, medium, or low cytoplasmatic expression, respectively (p<0.0005). Cytoplasmatic PARP expression reached statistically significance (p<0.0005) in univariate logistic regression analysis. In multivariate regression analysis age, hormone, and HER2 receptor status remained significant predictors of pCR, and cytoplasmatic PARP expression revealed borderline significance (p=0.078). Tumor grade lost all its predictive value. No such correlations were found regarding nuclear PARP staining. Conclusions: Cytoplasmatic PARP expression can be detected by immunohistochemistry in all subtypes of early breast cancers and is correlated with an aggressive biological tumour pattern. Cytoplasmatic PARP expression predicts pCR to neoadjuvant taxane-anthracycline-based chemotherapy. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Amgen, AstraZeneca, Bristol-Myers Squibb, Roche, sanofi-aventis Amgen, AstraZeneca, Roche, sanofi-aventis
Skin Lesions in Melanoma and Kaposi’s Sarcoma
Authors: Maria A. Pizzichetta, Vincenzo Canzonieri, Alessandro Gatti, Clelia de Giacomi, Giusto Trevisan, Andrea Veronesi, H. Peter Soyer
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.5.1412 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11870188 Skin Lesions in Melanoma and Kaposi’s Sarcoma Case 2. Dermoscopic Features of Metastases From Cutaneous Melanoma Mimicking Benign Nevi and Primary Melanoma Maria A. PizzichettaxMaria A. PizzichettaSearch for articles by this author , Vincenzo CanzonierixVincenzo CanzonieriSearch for articles by this author , Alessandro GattixAlessandro GattiSearch for articles by this author , Clelia de GiacomixClelia de GiacomiSearch for articles by this author , Giusto TrevisanxGiusto TrevisanSearch for articles by this author , Andrea VeronesixAndrea VeronesiSearch for articles by this author , H. Peter SoyerxH. Peter SoyerSearch for articles by this author Show More National Cancer Institute, Aviano, and University of Trieste, Trieste, Italy, and University of Graz, Graz, Austria https://doi.org/10.1200/JCO.2002.20.5.1412 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
PAX4 Gene Transfer Induces α-to-β Cell Phenotypic Conversion and Confers Therapeutic Benefits for Diabetes Treatment
Authors: Yanqing Zhang, Genevieve E Fava, Hongjun Wang, Franck Mauvais-Jarvis, Vivian A Fonseca, Hongju Wu
Journal: Molecular Therapy (2015)

The transcription factor Pax4 plays a critical role in the determination of α- versus β-cell lineage during endocrine pancreas development. In this study, we explored whether Pax4 gene transfer into α-cells could convert them into functional β-cells and thus provide therapeutic benefits for insulin-deficient diabetes. We found that Pax4 delivered by adenoviral vector, Ad5.Pax4, induced insulin expression and reduced glucagon expression in αTC1.9 cells. More importantly, these cells exhibited glucose-stimulated insulin secretion, a key feature of functional β-cells. When injected into streptozotocin-induced diabetic mice, Pax4-treated αTC1.9 cells significantly reduced blood glucose, and the mice showed better glucose tolerance, supporting that Pax4 gene transfer into αTC1.9 cells resulted in the formation of functional β-cells. Furthermore, treatment of primary human islets with Ad5.Pax4 resulted in significantly improved β-cell function. Detection of glucagon(+)/Pax4(+)/Insulin(+) cells argued for Pax4-induced α-to-β cell transitioning. This was further supported by quantification of glucagon and insulin bi-hormonal cells, which was significantly higher in Pax4-treated islets than in controls. Finally, direct administration of Ad5.Pax4 into the pancreas of insulin-deficient mice ameliorated hyperglycemia. Taken together, our data demonstrate that manipulating Pax4 gene expression represents a viable therapeutic strategy for the treatment of insulin deficient diabetes.
Abstract 13547: Role of Foxp3 Regulatory T Cell and Adiponectin Expression in Functional Recovery of Fulminant Myocarditis Patients Necessitating Ventricular Assist Device
Authors: Sokichi kamata, Shigeru Miyagawa, Satsuki Fukushima, Atsuhiro Saito, Norikazu Maeda, Hiroyuki Nishi, Yasushi Yoshioka, Daisuke Yoshioka, Tetsuya Saito, Koichi Toda, Iichiro Shimomura, Yoshiki Sawa
Journal: Circulation (2012)

Background: It has been shown that initiation and progression of fulminant myocarditis are associated with viral infection and/or immune disorders. Foxp3 regulatory T cell (Treg), which is characte...
A Comparison of Proposed Biosimilar and Originator Filgrastim for the Prevention of Neutropenia in Patients with Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Phase III, Randomized, Double-Blind Trial (The PIONEER study)
Authors: Kimberly Blackwell, Vladimir Semiglazov, Pedro Gascon, Roumen Nakov, Stefan Kramer, Arnd Schwebig, Nadia Harbeck
Journal: Blood (2014)
Phase II trial of chemotherapy with temozolomide in combination with topotecan for central nervous system (CNS) metastases of solid tumors.
Authors: P. Z. New, J. Jac
Journal: Journal of Clinical Oncology (2010)

TPS145 Background: Patients with brain metastases of solid tumors have a poor prognosis, despite improvements in survival achieved with modern neurosurgical and radiation techniques. Chemotherapy does not play any significant role in this disease, but may have application in salvage of patients who have failed radiation therapy. In patients who are not surgical candidates, do not require immediate XRT to relieve symptoms and have controlled systemic disease, effective chemotherapy as an alternative to XRT might decrease the risk of radiation induced neurotoxicity. Both temozolomide and topotecan have good blood-brain barrier penetration and have shown activity in CNS malignancies. Preclinical studies suggest synergy of this drug combination. This is a single-arm, open-label phase II drug study. All patients will receive the chemotherapy combination. Up to 35 patients will be accrued over 2-3 years and followed for up to 5 years. Patients will receive up to 8 cycles of chemotherapy. The primary endpoint is the rate of radiologic response of brain metastases and secondary endpoints are median overall survival, progression-free survival, time to progression of brain metastases and toxicity. Methods: Each cycle is defined as a 28-day period. Patients will take oral temozolomide at bedtime nightly for 5 days on days 1 through 5 of each cycle. A chemotherapy-trained nurse will administer topotecan intravenously daily for 5 days on days 2 through 6 of each cycle. Contrast-enhanced MRI or CT scan of the brain and the sites of extracranial disease will be performed at baseline and every 2 cycles, until completion of the therapy or progression to evaluate response. Patients achieving complete remission (CR) will receive 2 more cycles of combined chemotherapy after CR is documented, but no less than 6 and no more than 8 cycles total. To be eligible: 1) Have failed prior WBRT or 2) not be candidates for surgical intervention and not require immediate radiation therapy to relieve symptoms, and have controlled systemic disease. No significant financial relationships to disclose.
Abstract 15266: Left Ventricular Dyssynchrony Is Associated with Recurrence of Ischemic Mitral Regurgitation After Restrictive Annuloplasty
Authors: Leen van Garsse, Sandro Gelsomino, Fabiana Luca, Emile Cheriex, Carmelo Massimiliano Rao, Roberto Lorusso, Gian Franco Gensini, Jos G Maessen
Journal: Circulation (2011)

Background: In our study, we investigated the impact of papillary muscle systolic dyssynchrony (DYS-PAP) with 2D speckle-tracking echocardiography (2D-STE) analysis in the prediction of recurrent i...